Literature DB >> 434019

Mechanism of failed labor after fetal death and its treatment with prostaglandin E2.

H Schulman, L Saldana, C C Lin, G Randolph.   

Abstract

Pregnancy was terminated with prostaglandin E2 in 65 women harboring a dead fetus for 3 days to 8 weeks. The study was designed to: (1) elucidate the mechanism of failed onset of labor in the presence of fetal death, (2) determine appropriate dose-response relationships, and (3) evaluate safety and efficacy of this new method of intervention. Results indicate that plasma progesterone levels from 12 to 40 weeks' gestation are in the lower normal statistical range as compared to those seen in pregnancy with a living fetus. Uterine size as estimated from fetal birth weight is also in the low normal range compared to that seen in a viable pregnancy. Hence the uterine volume-progesterone ratio is equal to or greater than that in normal pregnancy and thereby partially explanatory for the failed initiation of labor. The dosage required to produce delivery declined in each month's grouping from a mean of 56 +/- 26 (SD) mg at 12 to 15 weeks to 22 +/- 8.4 mg at 38 to 40 weeks. Dose-delivery response did not correlate with age, parity, or progesterone levels but did correlate with oxytocin response. Three unusual and serious complications occured.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 434019     DOI: 10.1016/0002-9378(79)90111-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  Prevalence of coagulation abnormalities associated with intrauterine fetal death.

Authors:  A D Maslow; T W Breen; M C Sarna; A K Soni; J Watkins; N E Oriol
Journal:  Can J Anaesth       Date:  1996-12       Impact factor: 5.063

2.  A randomized controlled trial of misoprostol and sulprostone to end pregnancy after fetal death.

Authors:  Kristin Van Mensel; Filip Claerhout; Patrick Debois; Marc J N C Keirse; Myriam Hanssens
Journal:  Obstet Gynecol Int       Date:  2009-09-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.